Control Bionics (ASX:CBL) Retained Earnings: A$-39.00 Mil (As of Dec. 2025)


What is Control Bionics Retained Earnings?

Control Bionics ASX:CBL +2.74% Retained Earnings is A$-39.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Control Bionics's retained earnings for the quarter that ended in Dec. 2025 was A$-39.00 Mil.

Control Bionics's quarterly retained earnings declined from Dec. 2024 (A$-32.50 Mil) to Jun. 2025 (A$-35.39 Mil) and declined from Jun. 2025 (A$-35.39 Mil) to Dec. 2025 (A$-39.00 Mil).

Control Bionics's annual retained earnings declined from Jun. 2023 (A$-23.37 Mil) to Jun. 2024 (A$-29.28 Mil) and declined from Jun. 2024 (A$-29.28 Mil) to Jun. 2025 (A$-35.39 Mil).

Control Bionics  (ASX:CBL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Control Bionics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Control Bionics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Retained Earnings Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial -11.63 -17.73 -23.37 -29.28 -35.39

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.56 -29.28 -32.50 -35.39 -39.00

Control Bionics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-39.00 Mil mean?
Control Bionics (ASX:CBL) has a Retained Earnings of A$-39.00 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Control Bionics and its competitors.
Is Control Bionics' Retained Earnings too high?
Control Bionics' current Retained Earnings is A$-39.00 Mil.
How does Control Bionics' Retained Earnings compare to ABT and SYK?
Control Bionics' Retained Earnings of A$-39.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Control Bionics and its competitors. Control Bionics's current Retained Earnings is A$-39.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 150% above its estimated fair value. The current Retained Earnings is A$-39.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Retained Earnings is A$-39.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.